论文部分内容阅读
研究对象为60名健康口腔系医学生(男46名,女14名,平均年龄为26.4岁)。全部研究对象在受试前HBsAg、抗-HBs、抗HBc阴性,丙氨酸转氨酶(ALT)正常,无过敏性疾病史。于0、1、6月在受试者三角肌处肌肉注射20μg重组乙型肝炎疫苗。对首剂疫苗注射后12个月抗-HBs应答<100mIUml~(-1)的14例受试者进行加强剂量疫苗免疫接种。于接种前及接种后1、3、6、7、12、24和36个月系集血标本。每次接种疫苗后,连续5天测量体温,并记录局部和全身的副作用。结果表明,在第3剂疫苗注射后,98.3%的接种者(59/60)抗-HBs滴度大于10 mIU
The subjects were 60 healthy oral medical students (46 males and 14 females with a mean age of 26.4 years). All subjects had HBsAg, anti-HBs, anti-HBc negative, normal alanine aminotransferase (ALT) before the test, and no history of allergic diseases. At 0, 1, 6 months, 20 μg recombinant hepatitis B vaccine was intramuscularly injected into the deltoid muscle of the subject. Forty subjects with anti-HBs response <100 mIUml ~ (-1) at 12 months after the first dose of vaccine were boosted with booster dose vaccination. Blood samples were collected before inoculation and at 1, 3, 6, 7, 12, 24 and 36 months after inoculation. After each vaccination, body temperature was measured for 5 days and the local and systemic side effects were recorded. The results showed that 98.3% of vaccinated (59/60) anti-HBs titers were greater than 10 mIU after the third dose of vaccine